BMS 986447
Alternative Names: BMS-986447Latest Information Update: 29 Mar 2023
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 Mar 2023 Preclinical trials in Unspecified in USA (PO), before March 2023
- 09 Mar 2023 Bristol-Myers Squibb plans a phase I trial in Healthy participants